Polyphosphate, an active molecule derived from probiotic Lactobacillus brevis, improves the fibrosis in murine colitis

Translational Research

Volumn 166, Issue 2, 2015, Pages 163-175

  Kashima, Shin ^a   Fujiya, Mikihiro ^a   Konishi, Hiroaki ^a   Ueno, Nobuhiro ^a   Inaba, Yuhei ^a   Moriichi, Kentaro ^a   Tanabe, Hiroki ^a   Ikuta, Katsuya ^a   Ohtake, Takaaki ^a   Kohgo, Yutaka ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; CONNECTIVE TISSUE GROWTH FACTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; POLYPHOSPHATE; PROBIOTIC AGENT; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; COLLAGEN; CYTOKINE; DEXTRAN SULFATE; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRUSH BORDER; CHRONIC INFLAMMATION; CONTROLLED STUDY; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DOWN REGULATION; DRUG MECHANISM; EXPERIMENTAL COLITIS; FIBROBLAST; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTESTINAL FIBROSIS; INTESTINE EPITHELIUM CELL; INTESTINE INJURY; LACTOBACILLUS BREVIS; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TH1 CELL; TRINITROBENZENESULFONIC ACID INDUCED COLITIS; UPREGULATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CACO 2 CELL LINE; CHEMICALLY INDUCED; CHEMISTRY; CHRONIC DISEASE; COLITIS; COLON; DRUG EFFECTS; EPITHELIUM CELL; FIBROSIS; INFLAMMATION; METABOLISM; PATHOLOGY;

ANIMALS; CACO-2 CELLS; CHRONIC DISEASE; COLITIS; COLLAGEN; COLON; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINES; DEXTRAN SULFATE; EPITHELIAL CELLS; FIBROSIS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LACTOBACILLUS BREVIS; MACROPHAGES; MICE, INBRED C57BL; POLYPHOSPHATES; PROBIOTICS; TRANSFORMING GROWTH FACTOR BETA1; TRINITROBENZENESULFONIC ACID; UP-REGULATION;

EID: 84937633258     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2015.02.002     Document Type: Article

References (41)

1. R.W. Padgett, P. Das, and S. Krishna TGF-beta signaling, Smads, and tumor suppressors Bioessays 20 1998 382 390
2. M. Kretzschmar, and J. Massague SMADs: mediators and regulators of TGF-beta signaling Curr Opin Genet Dev 8 1998 103 111
3. A.K. Ghosh, W. Yuan, Y. Mori, and et al. Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-beta involves functional cooperation with p300/CBP transcriptional coactivators Oncogene 19 2000 3546 3555
4. G.E. Hume, E.V. Fowler, D. Lincoln, and et al. Angiotensinogen and transforming growth factor beta1: novel genes in the pathogenesis of Crohn's disease J Med Genet 43 2006 e51
5. B. Tamizifar, K.B. Lankarani, S. Naeimi, and et al. Promoter polymorphism of transforming growth factor-beta1 gene and ulcerative colitis World J Gastroenterol 14 2008 243 247
6. T. Mori, S. Kawara, M. Shinozaki, and et al. Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: a mouse fibrosis model J Cell Physiol 181 1999 153 159
7. J. Qin, R. Li, J. Raes, and et al. A human gut microbial gene catalogue established by metagenomic sequencing Nature 464 2010 59 65
8. S. Devkota, Y. Wang, M.W. Musch, and et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice Nature 487 2012 104 108
9. A.L. D'Souza, C. Rajkumar, J. Cooke, and et al. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis BMJ 324 2002 1361
10. L.V. McFarland Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease Am J Gastroenterol 101 2006 812 822
11. A. Bin-Nun, R. Bromiker, M. Wilschanski, and et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates J Pediatr 147 2005 192 196
12. H.C. Lin, B.H. Su, A.C. Chen, and et al. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants Pediatrics 115 2005 1 4
13. B.J. Rembacken, A.M. Snelling, P.M. Hawkey, and et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial Lancet 354 1999 635 639
14. P. Gionchetti, F. Rizzello, U. Helwig, and et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial Gastroenterology 124 2003 1202 1209
15. W. Kruis, P. Fric, J. Pokrotnieks, and et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine Gut 53 2004 1617 1623
16. K. Kato, S. Mizuno, Y. Umesaki, and et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis Aliment Pharmacol Ther 20 2004 1133 1141
17. R. Bibiloni, R.N. Fedorak, G.W. Tannock, and et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis Am J Gastroenterol 100 2005 1539 1546
18. M.A. Zocco, L.Z. dal Verme, F. Cremonini, and et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis Aliment Pharmacol Ther 23 2006 1567 1574
19. M. Fujiya, M.W. Musch, Y. Nakagawa, and et al. The Bacillus subtilis quorum-sensing molecule CSF contributes to intestinal homeostasis via OCTN2, a host cell membrane transporter Cell Host Microbe 1 2007 299 308
20. K. Okamoto, M. Fujiya, T. Nata, and et al. Competence and sporulation factor derived from Bacillus subtilis improves epithelial cell injury in intestinal inflammation via immunomodulation and cytoprotection Int J Colorectal Dis 27 2012 1039 1046
21. N. Ueno, M. Fujiya, S. Segawa, and et al. Heat-killed body of Lactobacillus brevis SBC8803 ameliorates intestinal injury in a murine model of colitis by enhancing the intestinal barrier function Inflamm Bowel Dis 17 2011 2235 2250
22. S. Segawa, M. Fujiya, H. Konishi, and et al. Probiotic-derived polyphosphate enhances the epithelial barrier function and maintains intestinal homeostasis through integrin-p38 MAPK pathway PLoS One 6 2011 e23278
23. F. Yan, H. Cao, T.L. Cover, and et al. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth Gastroenterology 132 2007 562 575
24. F. Yan, H. Cao, T.L. Cover, and et al. Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism J Clin Invest 121 2011 2242 2253
25. S. Melgar, A. Karlsson, and E. Michaelsson Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation Am J Physiol Gastrointest Liver Physiol 288 2005 G1328 G1338
26. I. Okayasu, S. Hatakeyama, M. Yamada, and et al. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice Gastroenterology 98 1990 694 702
27. S. Mahavadi, R.S. Flynn, J.R. Grider, and et al. Amelioration of excess collagen IαI, fibrosis, and smooth muscle growth in TNBS-induced colitis in IGF-I(+/-) mice Inflamm Bowel Dis 17 2011 711 719
28. M. Daigneault, J.A. Preston, H.M. Marriott, and et al. The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages PLoS One 5 2010 e8668
29. F. Obermeier, G. Kojouharoff, W. Hans, and et al. Interferon-gamma (IFN-gamma)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice Clin Exp Immunol 116 1999 238 245
30. C.O. Elson, K.W. Beagley, A.T. Sharmanov, and et al. Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance J Immunol 157 1996 2174 2185
31. S.J. Allen, B. Okoko, E. Martinez, and et al. Probiotics for treating infectious diarrhoea Cochrane Database Syst Rev 2004 CD003048
32. B.C. Johnston, A.L. Supina, M. Ospina, and et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea Cochrane Database Syst Rev 2 2007 CD004827
33. T. Mimura, F. Rizzello, U. Helwig, and et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis Gut 53 2004 108 114
34. S. Matsumoto, T. Hara, T. Hori, and et al. Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells Clin Exp Immunol 140 2005 417 426
35. M. Hoffmann, A. Messlik, S.C. Kim, and et al. Impact of a probiotic Enterococcus faecalis in a gnotobiotic mouse model of experimental colitis Mol Nutr Food Res 55 2011 703 713
36. N. Kamada, N. Inoue, T. Hisamatsu, and et al. Nonpathogenic Escherichia coli strain Nissle1917 prevents murine acute and chronic colitis Inflamm Bowel Dis 11 2005 455 463
37. M. Schultz, C. Veltkamp, L.A. Dieleman, and et al. Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice Inflamm Bowel Dis 8 2002 71 80
38. K.L. Madsen, J.S. Doyle, L.D. Jewell, and et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice Gastroenterology 116 1999 1107 1114
39. S.B. Hanauer, B.G. Feagan, G.R. Lichtenstein, and et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet 359 2002 1541 1549
40. B.E. Sands, F.H. Anderson, C.N. Bernstein, and et al. Infliximab maintenance therapy for fistulizing Crohn's disease N Engl J Med 350 2004 876 885
41. J.F. Colombel, W.J. Sandborn, P. Rutgeerts, and et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial Gastroenterology 132 2007 52 65